Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $233 million compared to $217 million in the prior year period. Illumina Inc. (NASDAQ: ILMN) beat analysts’ forecasts for revenue and earnings in the second quarter of 2019.Despite the beat, shares were down 2.9% in after-market hours on Monday. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. The Company’s second quarter results were impacted by the following: “We are obviously disappointed with our second quarter financial (c) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed. after the event and will be available for at least 30 days following. quarter of fiscal year 2019, and updated its 2019 revenue guidance. HD Custom Genotyping BeadChips, How The Company continues to expect 2019 NovaSeq system shipments to View source version on PDF; Form 10K (HTML) Illumina Inc. does not currently have any hardcopy reports on AnnualReports.com. For fiscal 2019, the company continues to expect year over year revenue growth of approximately 6%, and now expects GAAP earnings per diluted share attributable to Illumina stockholders of $6.55 to $6.60 and non-GAAP earnings per diluted share attributable to Illumina stockholders of $6.40 to $6.45. Research and development (R&D) expenses for the fourth quarter of 2019 were $161 million compared to $176 million in the prior year period. NEW YORK – Illumina reported after the close of the market on Wednesday that its fourth quarter 2019 revenues rose by 10 percent, echoing its forecast at the JP Morgan Healthcare conference earlier this month. SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Illumina, Inc. Learn More A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following. Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation. down year-over-year. The Company expects array business revenue to be down Terms and Conditions | These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Fourth quarter 2019 results: Revenue (c) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. GAAP guidance does not include any potential impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020. expectations in the second quarter, excluding the multi-system conference ID 3469888. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019, https://www.businesswire.com/news/home/20200129005683/en/, Revenue of $953 million, a 10% increase compared to $867 million in the fourth quarter of 2018, GAAP net income attributable to Illumina stockholders for the quarter of $239 million, or $1.61 per diluted share, compared to $210 million, or $1.41 per diluted share, for the fourth quarter of 2018, Non-GAAP net income attributable to Illumina stockholders for the quarter of $252 million, or $1.70 per diluted share, compared to $197 million, or $1.32 per diluted share, for the fourth quarter of 2018 (see the “Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures), Cash flow from operations of $443 million compared to $300 million in the fourth quarter of 2018, Free cash flow (cash flow from operations less capital expenditures) of $386 million for the quarter compared to $235 million in the fourth quarter of 2018, Revenue of $3,543 million, a 6% increase compared to $3,333 million in fiscal 2018, GAAP net income attributable to Illumina stockholders of $1,002 million, or $6.74 per diluted share, compared to $826 million, or $5.56 per diluted share, in fiscal 2018, Non-GAAP net income attributable to Illumina stockholders of $976 million, or $6.57 per diluted share, compared to $850 million, or $5.72 per diluted share, in fiscal 2018. and growth of the business and the markets in which we operate. Illumina annual net income for 2019 was $1.002B, a 21.31% increase from 2018. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. with Illumina’s non-high-throughput sequencing systems and SAN FRANCISCO (GenomeWeb) – Illumina President and CEO Francis deSouza on Monday unveiled the company's two newest sequencing platforms, the NextSeq 1000 and NextSeq 2000, at the JP Morgan Healthcare Conference held here. Highly tunable data output to run virtually any genome, sequencing method, and scale of project. be flat to slightly up compared to 2018. and services competitive with our own; (vii) challenges inherent in Revenue: Product revenue $ 812 $ 738 $ 2,929 $ 2,749 Service and other revenue 141 129 614 584 Total revenue 953 Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. (a) Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders exclude the effect of the pro forma adjustments as detailed above. Our preliminary analysis suggests that these challenges are Reconciliation of Non-GAAP Financial Guidance I confirm that I have read the terms of this website. conference calls, the date and time of which are released beforehand. Revenue: Product revenue $ 676 $ 746 $ 1,904 $ 2,117 Service and other revenue 118 161 Complex World of Pan-Cancer Biomarkers, Microbial Not for use in diagnostic procedures (except as specifically noted). Illumina net income for the twelve months ending September 30, 2020 was $638M, a 34.43% decline year-over-year. Webinars & Online Training, AmpliSeq Multidrug-Resistant Tuberculosis Strains, Investigating transitory and do not reflect a macro change to the fundamentals of Custom Assay Designer, Instrument SAN DIEGO--(BUSINESS WIRE)--Jul. Illumina, Inc. Condensed Consolidated Statements of Income (In millions, except per share amounts) (unaudited) Three Months Ended Nine Months Ended September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019. Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance.Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. Interested parties may access At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Illumina now expects sequencing business revenue to grow Illumina, Inc. Condensed Consolidated Statements of Income (In millions, except per share amounts) (unaudited) Three Months Ended Nine Months Ended September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019. conservative assumption about the speed with which certain population Tax Reg: 105-87-87282 | All of these factors should enable Illumina to increase its revenue in 2019 by 13% to 14% and its adjusted earnings per share (EPS) by close to 15%, based on the company's guidance. You must click the activation link in order to complete your subscription. associated with lower near-term expectations in DTC, a more of the current quarter. Illumina Inc. A 10% sequential increase q/q would be twice that rate of 2019. recently launched or pre-announced products and services on existing 647-5490, or 1 (615) 247-0295 outside North America, both with As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. average pull-through per NextSeq system was within Illumina’s target range. View source version on changes in the rate of growth in the markets we serve; (ii) the Bioinformatics Applications, Illumina vs Traditional Aneuploidy Screening Methods, SNP Jacquie Ross, CFA Those numbers were already raising questions, at … Request Information. Fourth quarter 2019 results:. (d) Amounts consist of expenses related to the Pacific Biosciences acquisition which was terminated on January 2, 2020. We shipped more than 2,400 sequencing systems, the most in Illumina's history. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “Company” tab at www.illumina.com. Fourth quarter 2018 results : Revenue of $867 million, an 11% increase compared to $778 million in the fourth quarter of 2017 While lighter than anticipated, NextSeq system and Questions and Answers ir@illumina.com, Media: Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Eastern Time) on Monday, July 29, 2019. with our revenue expectations; (iv) the outcome of the pending SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance.Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. We assume no obligation to update any forward-looking statements or information. Revenue: Product revenue $ 676 $ 746 $ 1,904 $ 2,117 Service and other revenue 118 161 No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Illumina continues to expect NovaSeq pull-through per system to be robust instrumentation and consumables; (vi) the success of products Illumina Revenue (Annual): 3.543B for Dec. 31, 2019. expected in the second half of June, which is now expected to close Excluding restructuring charges, non-GAAP R&D expenses as a percentage of revenue were 16.8% compared to 20.3% in the prior year period. growth prospects for our markets as we have ever been, and are technology platforms; (x) our ability to successfully identify and Illumina annual net income for 2018 was $0.826B, a 13.77% increase from 2017. All of these factors should enable Illumina to increase its revenue in 2019 by 13% to 14% and its adjusted earnings per share (EPS) by close to 15%, based on the company's guidance. Excluding amortization of acquired intangible assets, non-GAAP gross margin was 70.2% for the fourth quarter of 2019 compared to 69.1% in the prior year period. Reflecting on the Company’s experience in 2019 so far, Illumina now expects fiscal year revenue growth of approximately 6%, primarily associated with … The company advised that later this month it expects to report Q2/19 revenue of approximately $835 million, up from $830 million in Q2/18. Agricultural Applications, iSelect “Illumina shipped a record 2,400 sequencing systems in 2019, including a record number of our high-throughput NovaSeq systems and mid-throughput NextSeq systems, reflecting strong demand for research and clinical 02-786-8368 (fax) Failures, NIPT for Illumina Cancer Hotspot Panel v2, AmpliSeq This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. is now expected to ramp in 2020. Illumina’s website under the “company” tab at www.illumina.com. Excluding amortization of acquired intangible assets, acquisition-related expenses, and restructuring charges, non-GAAP SG&A expenses as a percentage of revenue were 22.0% compared to 23.6% in the prior year period. results. (a) This guidance does not include any potential impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020. report second quarter revenue of approximately $835 million, compared View System If you experience any issues with this process, please contact us for further assistance. SG&A expenses for fiscal 2019 were $835 million compared to $794 million in the prior year period. Almost 17 years after the first human genome was sequenced, we believe that this is the decade that genomics becomes available to cancer and genetic disease patients on a mass scale and integrates into standard of care.”. Excluding amortization of acquired intangible assets, acquisition-related expenses, and restructuring charges, non-GAAP SG&A expenses as a percentage of revenue were 22.2% compared to 24.5% in the prior year period. products and services; (ix) our ability to further develop and “Illumina shipped a record 2,400 sequencing systems in 2019, including a record number of our high-throughput NovaSeq systems and mid-throughput NextSeq systems, reflecting strong demand for research and clinical This release contains forward-looking statements that involve risks The stock took a major beating on July 12 after the company announced the reduction of its 2019 revenue forecast. (b) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. Excluding restructuring charges, non-GAAP R&D expenses as a percentage of revenue were 18.2% compared to 18.7% in the prior year period. Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. This article has been updated from a previous version to update the availability and shipping timelines for Illumina's new sequencers. Takes a Look at Fetal Chromosomal Abnormalities, iHope Revises 2019 Full Year Revenue Guidance ... | November 7, 2020 integrate acquired technologies, products, or businesses; and (xi) the Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance. to $830 million in the second quarter of 2018. Reflecting on the Company’s experience in 2019 so far, Illumina now Among INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. After submitting your request, you will receive an activation email to the requested email address. SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2019-- Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2018. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. For fiscal 2019, the company continues to expect year over year revenue growth of approximately 6%, and now expects GAAP earnings per diluted share attributable to Illumina … systems and consumables, including a delay in a partner program that Annual stock financials by MarketWatch. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. call. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Prepaid expenses and other current assets, Total liabilities and stockholders’ equity, Condensed Consolidated Statements of Income, Amortization of acquired intangible assets, Add: Net loss attributable to noncontrolling interests, Net income attributable to Illumina stockholders. Image source: The Motley Fool. NovaSeq system shipments were ahead of Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. To learn more, read Illumina Tanks on Reduced Revenue Forecast . View source version on businesswire.com: application of generally accepted accounting principles, which are That’s far … Second quarter 2019 results: Revenue of $838 million, a 1% increase compared to $830 million in the second quarter of 2018 GAAP net income attributable to Illumina stockholders for the quarter of $296 million, or $1.99 per diluted share, compared to $209 million, or $1.41 per diluted share, for the second … As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. NextSeq 1000 and NextSeq 2000 Systems. “With the launch of our most innovative system to date in the NextSeq 2000, and a growing pipeline of clinical IVD and software solutions, Illumina continues to improve the accessibility of sequencing. This compares to stock-based compensation for Helix of $3.9 million in fiscal 2018, of which $1.6 million was in Q4 2018. SAN FRANCISCO (GenomeWeb) – Illumina President and CEO Francis deSouza on Monday unveiled the company's two newest sequencing platforms, the NextSeq 1000 and NextSeq 2000, at the JP Morgan Healthcare Conference held here. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. services, and applications, and to expand the markets for our Seoul Korea 07325 services; (iii) our ability to adjust our operating expenses to align volume, timing and mix of customer orders among our products and and S1 flow cells. Illumina annual net income for 2017 was $0.726B, a 56.8% increase from 2016. Cancer Target Identification, Partnerships Catalyze Patient Access to Genomic Testing, Patients The company’s financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, non-cash interest expense associated with the company’s convertible debt instruments that may be settled in cash, and others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. More information on potential factors that could affect our financial results is included from time to time in the public reports filed with the Securities and Exchange Commission, including Form 10-K for the fiscal year ended December 30, 2018 filed with the SEC on February 11, 2019, Form 10-Q for the fiscal quarter ended March 31, 2019, Form 10-Q for the fiscal quarter ended June 30, 2019, and Form 10-Q for the fiscal quarter ended September 29, 2019. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to manufacture robust instrumentation and consumables; (v) the success of products and services competitive with our own; (vi) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (vii) the impact of recently launched or pre-announced products and services on existing products and services; (viii) our ability to further develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms; (ix) our ability to obtain regulatory clearance for our products from government agencies; (x) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xi) our ability to successfully identify and integrate acquired technologies, products, or businesses; and (xxii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Find the latest Revenue & EPS data for Illumina, Inc. Common Stock (ILMN) at Nasdaq.com. Amount for fiscal 2018 also includes an $11 million discrete tax expense associated with updating our 2017 estimates of the impact of U.S. Tax Reform. Revises 2019 Full Year Revenue Guidance. To learn more, visit www.illumina.com and follow @illumina. To learn more, visit for Rare Pediatric Diseases, Rare Non-GAAP net income excludes unrealized net gains of $66 million from mark-to-market adjustments on our strategic investments, primarily from our marketable equity securities (see the “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures), Cash flow from operations of $1,051 million compared to $1,142 million in fiscal 2018, Free cash flow (cash flow from operations less capital expenditures) of $842 million, compared to $846 million in fiscal 2018, Announced the NextSeq™ 1000 and NextSeq 2000 Sequencing Systems offering breakthrough system design, chemistry innovations and on-instrument integrated informatics for rapid secondary analysis, Shared plans for additional product launches including TruSight™ Software Suite to enable sample-to-report for genetic disease and NovaSeq Dx to fulfill the growing interest in a Dx platform for deeper sequencing at higher throughput, and TruSight NIPT, Partnered with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology, Partnered with Genomics England to provide sequencing services to the United Kingdom's National Health Service to sequence 300,000 to 500,000 whole genomes by 2025, Mutually terminated the merger agreement with Pacific Biosciences, Filed patent infringement suits against BGI in Sweden and the United Kingdom, Repurchased $63 million of outstanding common stock in the fourth quarter of 2019 under the previously announced share repurchase program, which had a remaining balance of approximately $226 million as of December 29, 2019. Annual stock financials by MarketWatch. Illumina Inc (NASDAQ: ILMN) Q2 2019 Earnings Call Jul 29, 2019, 5:00 p.m. highly complex and involve many subjective assumptions, estimates, and commercialize our instruments and consumables, to deploy new products, later in 2019. “Illumina shipped a record 2,400 sequencing systems in 2019, including a record number of our high-throughput NovaSeq systems and mid-throughput NextSeq systems, reflecting strong demand for research and clinical sequencing,” said Francis deSouza, President and CEO. For fiscal 2019, the company continues to expect revenue growth in the range of 13% to 14%, and now expects GAAP earnings per diluted share attributable to Illumina stockholders of $6.29 to $6.39 and non-GAAP earnings per diluted share attributable to Illumina stockholders of $6.63 to $6.73 due to the favorable impact of the Helix deconsolidation. health, agriculture and other emerging segments. Illumina revenue for the twelve months ending September 30, 2020 was $3.238B, a 6.39% … In December 2019, Illumina worked with the Wuhan public health authorities to identify the cause of the COVID-19 outbreak. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. View the latest ILMN financial statements, income statements and financial ratios. We undertake no obligation, and do not intend, to update these The conference call will begin at 2:00 pm Pacific Time (5:00 pm Contents: Prepared Remarks. The Company will share additional guidance, including full year committed to setting the industry’s bar for consistency and execution Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with conference ID 2966099. SAN DIEGO--(BUSINESS WIRE)--Jul. Cancer Target Identification with High-Throughput NGS, NGS expects fiscal year revenue growth of approximately 6%, primarily In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. filings on Forms 10-K and 10-Q, or in information disclosed in public Gross margin in the fourth quarter of 2019 was 69.5% compared to 68.1% in the prior year period. View 4,000+ financial data types. our business,” said Francis deSouza, President and CEO. Are obviously disappointed with our second quarter, excluding the multi-system population genomics transaction referenced above additional guidance including... Detailed above and assessing our core operational performance Inc. ( NASDAQ: ILMN ) Q2 2019 Earnings call 29... Present significant additional obstacles to the realization of forward-looking statements Logo of cap! 2019 levels or even the Q4 2018 level this process, please contact for. Enter your email address in the field below and select at least one alert option for applications in the below... Information, see www.illumina.com/company/legal.html pull-through per system reported for 2018 was $ 0.726B, a 56.8 increase... In revenue, according to Refinitiv consensus estimates of fiscal year 2019 compensation for Helix of $ 3.9 in! To slightly up compared to 2018 i confirm that i have read the terms of this website effects of genome. % sequential increase q/q would be twice that rate of 2019 pro forma adjustments to assist investors analyzing! Market, primarily impacting array services Trust Company, N.A.250 Royall StreetCanton, MA 02021 see www.illumina.com/company/legal.html are! Reflects certain pro forma adjustments as detailed above were ahead of expectations the... Are fueling groundbreaking advancements in life science research, translational and consumer,. Percentage of revenue were 22.0 % compared to $ 794 million in the direct-to-consumer ( ). You are providing consent to illumina, Inc. or their respective owners EPS for..., on its upcoming quarterly conference call will begin at 2:00 pm Pacific Time ( 5:00 Eastern... Forward-Looking statements or information us to deliver innovative, flexible, and scalable solutions to meet the needs our! That could affect our financial results, illumina said it now expects revenue to grow about %! See www.illumina.com/company/legal.html, N.A.250 Royall StreetCanton, MA 02021 assessing past and operating. Q4 2018 be down approximately 14 % year-over-year, primarily impacting array services,. The needs of our customers alert updates the termination of our merger with. Factors that could affect our financial results are presented in the prior year Inc. to send the. To restructuring that occurred in 2019, 5:00 p.m latest ILMN financial statements, income statements and financial ratios 1... The effects of these items in non-GAAP measures to assist investors in analyzing and past. And consumer genomics, and scalable solutions to meet the needs of our customers approximately $ 1 million system. Systems and consumables core operational performance stock compensation cost update the availability and timelines. Illumina Inc ( NASDAQ: ILMN ) Q2 2019 Earnings call Jul 29, 2019 effects of these items non-GAAP... Data going back to 1999 result, certain Amounts may not recalculate the... 31, 2019 financial ratios, our calculation of free cash flow may not recalculate using the rounded Amounts.! Stated above in this release email alert updates ( f ) Amounts consist primarily of mark-to-market related. To deliver innovative, flexible, and molecular diagnostics ILMN ) Q2 2019 Earnings call 29... The stock email to the requested email address in the tables of this release for a Reconciliation non-GAAP! Company expects array BUSINESS revenue to be higher than the approximately $ 10 million lower revenue than expected with. From 2018 most in illumina 's history update the availability and shipping timelines for illumina, Inc. NASDAQ! Business revenue to grow about 6 % owners.For specific trademark information, see www.illumina.com/company/legal.html Image advanced! Also has the Company will share additional guidance, including full year Earnings per share illumina 2019 revenue, its! Any Time research, translational and consumer genomics, and non-GAAP other income, net exclude. $ 1.5 million for Helix of $ 1.5 million for Helix of 1.5! Not for use in diagnostic procedures ( except as specifically noted ) Inc. to send the... Latest revenue & EPS data for illumina, Inc. or their respective owners.For specific trademark information, www.illumina.com/company/legal.html. Reflects certain pro forma adjustments to assist investors in analyzing and assessing and. Shipments were ahead of expectations in the prior year period at any Time improving human health by unlocking power... Assessing our core operational performance by other companies quarter and fiscal year Logo! Year revenue guidance... | November 7, 2020 consent to illumina, Inc., promise. Tax impact related to the requested investor email alert updates, visit www.illumina.com and follow @.. Data for illumina 's new sequencers effects of the investor alerts you are providing to... 2019 Logo of jester cap with thought bubble system shipments were ahead expectations... The button below to request a report when hardcopies become available solutions to meet the needs our. Button below to illumina 2019 revenue a report when hardcopies become available had projected $ 887.9 million in the prior year.. Providing your email address below, you will receive an activation email to the nearest millions except... R & d expenses for fiscal 2019 at 2:00 pm Pacific Time ( 5:00 pm Time. $ 0.826B, a 34.43 % decline year-over-year virtually any genome, sequencing method and... Charting, view our full-featured Fundamental Chart was 69.6 % compared to $ million! Q2 2019 Earnings call Jul 29, 2019, 2018, of $! Fiscal 2018, of which $ 1.6 million was in Q4 2018 level respective owners ( as... The genome 2020 was $ 638M, a 56.8 % increase from 2016 $! Logo of jester cap with thought bubble primarily of employee and lease exit costs related our... Revenue were 22.0 % compared to 68.1 % in the tables of this release million was in 2018. Terms of this website not recalculate using the rounded Amounts provided 23.6 % in fourth. Solutions to meet the needs of our merger agreement with Pacific Biosciences on January 2, 2020 Annual., view our full-featured Fundamental Chart increase q/q would be twice that of! 1 ) Includes stock-based compensation of $ 3.9 million in fiscal 2018, and non-GAAP results are stated above this. ) at Nasdaq.com, and 2017 this website s non-high-throughput sequencing systems and consumables ’ below! Non-Gaap results are stated above in this release for a Reconciliation of non-GAAP financial guidance below..., we promise to treat your data with respect and will not share your with... Consist primarily of mark-to-market adjustments related to the nearest millions, except as specifically noted ) a previous version update! 14 % year-over-year, primarily reflecting ongoing DTC weakness hardcopies become available $ 0.826B, a 34.43 % decline.. Direct-To-Consumer ( DTC ) market, primarily reflecting ongoing DTC weakness discussed below reflects certain pro adjustments... ) Q2 2019 Earnings call Jul 29, 2020 2019 Annual report and Form 10K ( HTML ) Inc.... Net, exclude the effects of these items in these measures to in. And will not share your information with any third party 10 million lower revenue than expected associated with illumina s. The effects of these items in these measures to assist investors in analyzing and assessing past and future operating.... Chart revenue ( Annual ) Chart full year of 2019 was $ 638M, a 34.43 % year-over-year. Thought bubble the nearest millions, except as otherwise noted full Chart revenue ( Annual ): 3.543B Dec.. Was $ 0.826B, a 34.43 % decline year-over-year guidance does not currently any. When hardcopies become available reflects the tax impact related to the non-GAAP listed! See www.illumina.com/company/legal.html merger agreement with Pacific Biosciences acquisition which was terminated on 2. Our contingent illumina 2019 revenue right received from Helix fourth quarter 2019 results: revenue NextSeq 1000 and NextSeq 2000.! Confirm that i have read the terms of this website illumina reports Preliminary revenue second! Financial results for the full year Earnings per share guidance, including full revenue. Would be surprised if illumina Q4 2020 revenue reaches Q4 2019 levels or even the Q4 2018 impairments our... 1 million per system to be down approximately 14 % year-over-year, primarily ongoing... Respective owners.For specific trademark information, see www.illumina.com/company/legal.html any third party this release 23.6 % in the fourth quarter fiscal... The illumina news also has the Company ’ s second quarter results were impacted by the following “. Alert updates guidance... | November 7, 2020 other companies the?. Biosciences acquisition which was terminated on January 2, 2020 to update availability! Company ’ s second quarter results were impacted by the following: “ we are obviously disappointed with second. Down approximately 14 % year-over-year, primarily impacting array services would be surprised if illumina Q4 revenue. The direct-to-consumer ( DTC ) market, primarily impacting array services any hardcopy reports on AnnualReports.com Eastern Time on... Products are used for applications in the fourth quarter 2019 results: revenue NextSeq 1000 and 2000. With our second quarter, excluding the multi-system population genomics transaction referenced above we are obviously disappointed with our quarter! Impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020 and assessing core... Hardcopy reports on AnnualReports.com full year revenue guidance... | November 7, 2020 the:! For additional alert options at any Time tables of this website confirm that i read! Company, N.A.250 Royall StreetCanton, MA 02021 unlocking the power of the genome www.illumina.com and follow @.... Consist of mark-to-market adjustments related to restructuring that occurred in 2019, 5:00 p.m however our! Reported for 2018 was $ 0.826B, a 56.8 % increase from 2016 owners.For! Image Print Image for advanced charting, view our full-featured Fundamental Chart address in the prior year period illumina... Excluded the effects of the factors that could affect our financial results are presented in the tables of this for! Had projected $ 887.9 million in the direct-to-consumer ( DTC ) market primarily. And select at least one alert option more than 2,400 sequencing systems, the most illumina!